8-K: Applied Therapeutics Stockholders Approve Reverse Split and Key Governance Measures

Applied Therapeutics, Inc. stockholders approved a reverse stock split, the election of a Class III director, auditor ratification, and executive compensation at their 2025 Annual Meeting.

Summary

• Stockholders of Applied Therapeutics, Inc. elected Teena Lerner, Ph.D., as a Class III director to serve until the 2028 Annual Meeting, with 44,287,976 votes For, 17,031,078 Abstentions, and 39,277,498 Broker Non-Votes.
• The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with 99,429,280 votes For, 679,553 Against, and 725,233 Abstentions.
• The non-binding advisory proposal to approve the compensation of named executive officers passed with 57,650,206 votes For, 3,307,662 Against, 598,700 Abstentions, and 39,277,498 Broker Non-Votes.
• Stockholders voted for an annual frequency for the advisory vote on executive compensation, with 60,589,660 votes for One Year, 144,599 for Two Years, 275,839 for Three Years, 546,470 Abstentions, and 39,277,498 Broker Non-Votes; the Company will hold this vote annually.
• An amendment to the Amended and Restated Certificate of Incorporation to effect a reverse stock split, at a ratio of not less than one-for-5 and not more than one-for-40, was approved with 92,238,511 votes For, 8,537,480 Against, and 58,075 Abstentions.

Sentiment

Score: 6

Explanation: The sentiment is generally neutral to slightly positive as all management-backed proposals passed, demonstrating shareholder support for the company's governance and strategic direction, including the flexibility to execute a reverse stock split. However, reverse stock splits are often viewed with caution by investors as they can sometimes signal underlying challenges or be followed by further price declines, which tempers the overall positive sentiment.

Positives

• All five proposals presented at the Annual Meeting were approved by the stockholders, indicating alignment with management's recommendations.
• The ratification of Ernst & Young LLP as the independent auditor received overwhelming support with 99,429,280 votes For.
• The approval of the reverse stock split amendment provides the Board of Directors with the flexibility to adjust the company's share structure, which could be beneficial for meeting listing requirements or attracting institutional investors.

Negatives

• A significant number of shares (39,277,498) were reported as broker non-votes for the director election and executive compensation advisory votes, indicating a portion of shares not voted on these discretionary matters.
• While approved, 8,537,480 shares voted against the reverse stock split amendment, indicating some shareholder dissent regarding this proposal.

Future Outlook

The Company will hold an advisory say-on-pay vote every one year in connection with its annual meeting of stockholders. The Board of Directors has been granted sole discretion to set the exact ratio for the approved reverse stock split within the range of one-for-5 to one-for-40.

Industry Context

This filing details routine corporate governance matters and a significant capital structure change (reverse stock split) for a publicly traded biotechnology company. Reverse stock splits are often undertaken by companies to increase their stock price, potentially to meet minimum bid price requirements for continued listing on exchanges like Nasdaq, or to make the stock more attractive to institutional investors.

Corporate Governance

Stakeholder Impact

• Shareholders: Will experience a reduction in the number of shares owned, with a proportional increase in share price, if the reverse stock split is implemented. Their voting rights and influence on corporate governance matters remain consistent.
• Management: Received shareholder approval for their proposed director, auditor, executive compensation, and the strategic flexibility of a reverse stock split, affirming their current direction.

Next Steps

• The Board of Directors will determine the exact ratio for the reverse stock split within the approved range of one-for-5 to one-for-40.
• The Company will continue to hold an advisory say-on-pay vote annually at its future annual meetings of stockholders.

Key Dates

Keywords

Applied Therapeutics, APLT, SEC Filing, 8-K, Stockholder Meeting, Annual Meeting, Reverse Stock Split, Corporate Governance, Director Election, Auditor Ratification, Executive Compensation, Say-on-Pay